GLP-1 Drugs and Gastroparesis: What the Evidence Can—and Cannot—Tell Us

First separate a mechanism from a diagnosis

GLP-1 receptor agonists lower glucose and appetite through several pathways, including slowing the movement of food from the stomach. That pharmacologic effect can contribute to fullness and post-meal glucose control. Gastroparesis, by contrast, is a clinical syndrome involving symptoms and objectively delayed gastric emptying without a mechanical obstruction. Nausea, vomiting, constipation or abdominal fullness can occur for many reasons and do not, by themselves, prove gastroparesis.

That distinction is central to both medicine and litigation. A study showing slower emptying after a standardized meal demonstrates a biologic effect under its protocol. A billing-code study may capture diagnosed gastroparesis in routine care. A lawsuit alleges that a particular product caused a particular injury. These are related layers of evidence, but none can simply substitute for the others. Diagnosis and treatment belong with qualified clinicians; legal sufficiency belongs to the court.

What controlled semaglutide studies measured

A randomized crossover study in 30 adults with obesity found once-weekly semaglutide delayed first-hour gastric emptying compared with placebo, measured indirectly through paracetamol absorption. A separate randomized crossover trial in 15 people with type 2 diabetes found oral semaglutide reduced first-hour paracetamol exposure by 31%, again indicating slower early emptying. These small studies were designed around pharmacodynamic effects, not the incidence of chronic gastroparesis across millions of users.

A 12-week placebo-controlled study in 20 women with obesity and polycystic ovary syndrome used scintigraphy, a direct imaging method. At four hours, the semaglutide group retained 37% of the solid meal versus no retention in the placebo group, and median half-emptying time was longer. The result shows substantial delayed emptying in that small selected population. It does not establish how often persistent symptomatic gastroparesis occurs after discontinuation or across other doses and patient groups.

What large observational studies add

A 2025 MarketScan cohort study examined people with obesity but without type 2 diabetes. It reported gastroparesis rates of 6.5 per 1,000 person-years among semaglutide users, compared with 2.1 for bupropion-naltrexone and 1.1 after sleeve gastrectomy. After adjustment, the reported hazard ratios were 3.33 and 6.14, respectively. Those results address real-world diagnosed events and use active comparators, but treatment groups can still differ in ways claims data do not fully measure.

A newer large active-comparator cohort in people with type 2 diabetes evaluated a composite of severe constipation, gastroparesis and gastrointestinal obstruction. It reported incidence rates of 1.02 versus 0.75 per 100 person-years for GLP-1-based therapies versus SGLT-2 inhibitors after matching. A composite does not reveal the full result for gastroparesis alone in a short summary. Diabetes itself can affect gastric motility, and follow-up, coding accuracy, adherence and channeling of higher-risk patients remain important limitations.

What current FDA labels say

Current Wegovy labeling states that the drug delays gastric emptying, warns that gastrointestinal adverse reactions can sometimes be severe, and says Wegovy is not recommended in patients with severe gastroparesis. The label also discusses pulmonary aspiration reports during anesthesia or deep sedation and the potential effect on absorption of some oral medicines. Ozempic labeling likewise describes delayed gastric emptying and product-specific gastrointestinal warnings. Exact language and revision dates matter; “GLP-1 label” is not one interchangeable document.

A warning or postmarketing report does not provide the incidence or prove causation in an individual case. Voluntary reports can be incomplete and lack a denominator. Conversely, the absence of the word “gastroparesis” in one section of an older label does not mean the known gastric-emptying effect was absent from pharmacology. The disciplined approach compares the relevant product and date, then asks what the label actually communicated to prescribers and patients.

How to interpret symptoms and legal claims responsibly

Persistent vomiting, inability to tolerate food, dehydration, severe abdominal pain or symptoms around anesthesia can require prompt medical attention. A clinician may review medication timing, diabetes control, other drugs, structural obstruction and objective testing. Patients should not change a prescribed medicine solely because of litigation content; stopping or switching can carry its own risks, especially for diabetes and cardiovascular disease.

For MDL 3094, plaintiffs allege GLP-1 products caused gastroparesis and other GI injuries and that warnings were inadequate; defendants deny the allegations. General scientific evidence may help answer whether a product is capable of causing an injury, while a specific case still turns on the actual medicine, exposure, symptom onset, objective diagnosis, alternative causes and governing law. The research supports careful surveillance and genuine uncertainty—not a universal causal conclusion or an online eligibility decision.

Reader questions

Frequently asked questions